» Articles » PMID: 29029067

Pharmacodynamics of Fosfomycin Against ESBL- And/or Carbapenemase-producing Enterobacteriaceae

Overview
Date 2017 Oct 14
PMID 29029067
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The increase in antibiotic resistance in Gram-negative bacteria and the limited therapeutic options due to the shortage of new antibiotics have increased the interest of the 'old' antibiotic fosfomycin in the treatment of infections. However, there are contradictory reports on the pharmacodynamics of and emergence of resistance to fosfomycin.

Methods: Time-kill assays were performed with 11 ESBL-positive and 3 ESBL-negative strains, exposing the bacteria to 2-fold static concentrations from 0.125× to 32× MIC. The sigmoid maximum effect (Emax) model was fitted to the time-kill curve data. Amplification of resistance over time was evaluated under various conditions of selective pressure by plating on 16× MIC plates.

Results: Fosfomycin was bactericidal for all strains within 8 h. Using the Emax model, no significant differences between strains were observed for the pharmacodynamic parameters. However, the large variation in Hill slope factors for Escherichia coli of 0.87 up to 4.02 indicates that the killing behaviour appears to be more time dependent for some strains but concentration dependent for others. In the fosfomycin-exposed cultures under low and high selective pressure (≥2× MIC) the median resistance proportions between the resistant and total population increased from ≤2 × 10-6 (T = 0 h) to 0.652-0.899 (T = 24 h). Resistance appeared stable after repeated subculturing.

Conclusions: Killing behaviour of fosfomycin does not only differ between species but also within species and may have an impact on the design of optimal dosing regimens. Although fosfomycin was bactericidal against all strains (re)growth of resistant subpopulations occurred relatively fast. This may limit the use of fosfomycin as a single drug therapy.

Citing Articles

The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy.

Anastasia A, Bonura S, Rubino R, Giammanco G, Micciche I, Di Pace M Antibiotics (Basel). 2023; 12(6).

PMID: 37370290 PMC: 10295113. DOI: 10.3390/antibiotics12060971.


Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study.

Konig C, Martens-Lobenhoffer J, Czorlich P, Westphal M, Bode-Boger S, Kluge S Ann Clin Microbiol Antimicrob. 2023; 22(1):29.

PMID: 37095559 PMC: 10127017. DOI: 10.1186/s12941-023-00572-4.


Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers.

Edwina A, Koch B, Muller A, Al Jalali V, Matzneller P, Zeitlinger M Eur J Clin Pharmacol. 2023; 79(6):775-787.

PMID: 37060459 PMC: 10229474. DOI: 10.1007/s00228-023-03477-5.


In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Clinical Isolates.

Ribeiro A, Chikhani Y, Valiatti T, Valencio A, Kurihara M, Santos F Antibiotics (Basel). 2023; 12(2).

PMID: 36830148 PMC: 9952190. DOI: 10.3390/antibiotics12020237.


Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.

Abbott I, van Gorp E, Wyres K, Wallis S, Roberts J, Meletiadis J J Antimicrob Chemother. 2022; 77(5):1324-1333.

PMID: 35211736 PMC: 9047678. DOI: 10.1093/jac/dkac045.